The use of tPA in thrombolytic therapy of ischemic stroke is limited due to adverse complications, including hemorrhage.1,55 Notably, increase in tPA expression (at 9 h) and activity (at 24 h) by PUR was associated with neuroprotection and reduction of BBB permeability. The gene discussed is PLAT; the disease is ischemic stroke.